Sanofi (EURONEXT: SAN) (NASDAQ: SNY) presented positive results from three phase 3 studies of amlitelimab for moderate-to-severe atopic dermatitis at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE